Background: In vitro hERG blockade assays alone provide insufficient information to accurately discriminate 10 "safe" from "dangerous" drugs. Recent studies have suggested that the integration of multiple ion channel 11 inhibition data can improve the prediction of drug-induced arrhythmogenic risks. In this study, using a family 12 of cardiac cell models representing electrophysiological heterogeneities across the ventricular wall, we 13 quantitatively evaluated transmural and rate-dependent properties of drug-induced arrhythmogenicity through 14 computer simulations of multichannel pharmacology. 15 Methods and Results: Rate-dependent drug effects of multiple ion channel inhibition on cardiac 16 electrophysiology at their effective free therapeutic plasma concentrations (EFTPCs) were investigated using 17 a group of in silico cell models (Purkinje (P) cells, endocardial (Endo) cells, mid-myocardial (M) cells and 18 epicardial (Epi) cells). We found that (1) M cells are much more sensitive than the other cell types to drug-19 induced arrhythmias and can develop early afterdepolarization (EAD) in response to bepridil, dofetilide, 20 sotalol, terfenadine, cisapride or ranolazine. (2) Most drug-induced adverse effects, such as pronounced action 21 potential prolongations or EADs, occur at slower pacing rates. (3) Although most drug-induced EADs occur 22 30
in M cells, the application of quinidine at its EFTPC can cause EADs in all four cell types. (4) The underlying 23 ionic mechanism of drug-induced EADs differs across different cell types; while INaL is the major depolarizing 24 current during the generation of EAD in P cells, ICaL is mostly predominant in other cell types. (5) Drug- 25 induced AP alternans with larger beat-to-beat variations occur at high pacing rates in mostly P cells, while the 26 application of bepridil can cause alternating EAD patterns at slower pacing rates in M cells.
27
Conclusions: In silico analysis of transmural and rate-dependent properties using multichannel inhibition data 28 can be useful to accurately predict drug-induced arrhythmogenic risks and can also provide mechanistic 29 insights into drug-induced adverse events related to cardiac arrhythmias.
Introduction 44 Drug-induced cardiotoxicity has been a major concern since the early stage of novel drug development. 45 Unexpected post-marketing occurrence of cardiotoxic effects remains a leading cause of drug withdrawal and 46 relabelling [1] [2] [3] . As defined by the International Conference of Harmonization Expert Working Group for all 47 drugs in development, QT interval prolongation has been used as a biomarker to predict the potential risk of 48 Torsade de Pointes (TdP) [4, 5] . Most drugs that prolong the QT interval inhibit cardiac potassium channels 49 encoded by human ether-à -go-go related gene (hERG); therefore, the level of hERG channel inhibition has 50 been the "gold standard" to predict the TdP risk. However, recent studies suggested that the in vitro hERG 51 blockade assay alone provides insufficient information to accurately discriminate "safe" from "dangerous" 52 drugs. For instance, QT prolongation can be induced by drugs that inhibit other ionic channels such as IKs, and 53 it has been known for years that the arrhythmia associated with hERG blockade is mitigated by concurrent 54 blockade of Na + or Ca 2+ channels [6, 7] . Other electrocardiogram (ECG) abnormalities, such as QT shortening 55 or T wave alternation, are also frequently associated with TdP. Recently, the Comprehensive in vitro 56 Proarrhythmia Assay (CiPA) has been proposed to address the misidentification issue of drug-associated TdP 57 risk based on hERG inhibition and QT prolongation data. This new paradigm is based on integrated assessment 58 of multiple ion channel dynamics in delayed ventricular repolarization; alterations to this process lead to 59 repolarization in stability and arrhythmias [8] . 60 Computational modelling of the heart has been an important tool in advancing our understanding of 61 cardiac excitation-contraction coupling. Recent studies have utilized mathematical modelling to evaluate the 62 4 drug-induced proarrhythmic risk [9] [10] [11] [12] . For example, multiple cardiac ion channels were integrated into the 63 human myocyte model to improve the assessment of proarrhythmic risk [13] . Additionally, research institutions 64 classify the cardiac toxicity of drugs through a computational approach that combines a human ventricular 65 myocyte model of drug effects and machine learning [14] . However, researchers have performed experiments 66 on only one cell type. Here, we employed a series of mathematical models and performed quantitative analyses 
Results
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Transmural heterogeneity of cardiac AP morphologies and adaptations 72 Transmural action potential (AP) morphologies are shown during steady-state pacing (cycle length 73 (CL)=1000 ms) and action potential duration (APD) rate adaptations ( Figure 1 ). The APD in mid-myocardial 74 (M) cells was longer than that in epicardial (Epi) cells or endocardial (Endo) cells and was considerably shorter 75 than the APD in Purkinje (P) cells. The AP amplitude in P cells was considerably higher than that in different 76 types of ventricular cells. In Epi and M cells, AP reproduced a characteristic phase 1 notch and dome 77 morphology, which was not apparent in Endo cells. In addition, the notch and dome morphology was absent 78 in simulated P cells. The APD was prolonged as the heart rate slowed down. The simulated cell AP 79 morphology and APD adaptation curve were consistent with previous experiments [18, 19] . 81 Drug-induced changes in AP adaptations were shown in Figure 2 . For bepridil, cisapride, terfenadine and 82 dofetilide, simulated APD was significantly prolonged (the percentage of prolongation>10%) in all cell types 83 and moderately prolonged for sotalol and ranolazine, and EAD was triggered exclusively in M cells. In 84 contrast, chlorpromazine, verapamil and ondansetron caused moderate prolongation, and diltiazem and 85 mexiletine led to minor APD shortening by 0.9% and 2.6% at CL=2000 ms in P cells, respectively, while 86 causing a positive shift of APD adaptation curves in other cells. Furthermore, at CL=1000 ms, cisapride caused 87 5 APD prolongation of 12.6%, 14.3% and 15.7% in P, Epi and Endo cells, respectively, while it caused APD 88 prolongation of 129.3% in M cells. In general, the percentages of drug-induced APD prolongations were much 89 higher in M cells. For example, at CL=1000 ms, bepridil caused APD prolongation of 15% (P cells), 27% (Epi 90 cells) and 25.6% (Endo cells) respectively, and caused APD prolongation of 158% in M cells. Drug-induced 91 changes in APD is highly dependent on pacing CLs or rates, with drug-induced EAD events mostly associated 92 with slower pacing rates. For example, in M cells, the percentage of APD prolongation of ranolazine was 7.5% 93 (CL=500 ms) and 9.4% (CL=1000 ms), while ranolazine induced EAD (102.9%) at CL=2000 ms. These 94 results suggested that M cells could be more sensitive in general to drug-induced APD prolongation and EAD 95 events, and interestingly P cells are more sensitive to AP alternans. giving rise to the pronounced prolongation of APD and occurrence of EAD ( Figure 4A ). Bepridil caused APD 114 prolongation of 31%, 158.1% and 255.2%, at CL=500 ms, 1000 ms, and 2000 ms, respectively. At CL=500 115 ms, IKr was a major current responsible for APD prolongation; inhibition of INaL could shorten APD, attenuate 116 the prolongation resulting from hERG (IKr) inhibition and prevent EAD ( Figure 4B ). 118 With the application of quinidine in all four types of cells at CL=2000 ms, large amplitude EADs 119 developed starting from the 133 rd beat in Endo cells ( Figure 5A ). Persistent EAD events occurred starting at 120 the 4 th beat in M cells, and these cells died at the 6 th beat ( Figure 5B ). EADs developed starting from the 3rd 121 beat in Epi cells ( Figure 5C ). Consecutive EADs were generated from the 1503 rd beat ( Figure 5D ). shown. In addition, the application of bepridil can also cause alternating EAD patterns at slower pacing rates 132 (CL=1050ms) in M cells. While major reduction in IKr was most responsible for drug-induced APD 133 prolongation, a smaller Ito could play the secondary role with the application of dofetilide ( Figure 6B) . 134 Furthermore, it was shown that INaL and ICaL could be the major currents responsible to induce AP alternans, 135 and Iks and INCX may function as protecting currents against AP alternans ( Figure 6B and 6C) . In this study, we quantitatively evaluated the transmural characteristics and rate dependence of drug-139 induced arrhythmogenicity through simulations of multichannel pharmacology using a family of cardiac cell 140 models. To address the misidentification of drug-associated TdP risk based solely on hERG and QT data, 141 Kramer et al. [20] published a predictive model that accounts for L-type Ca 2+ channel blockade in addition to 142 hERG blockade. This model improved discrimination between torsadogenic and nontorsadogenic drugs over 143 the hERG assay, and a new model that combines dynamic drug-hERG interactions and multichannel 144 pharmacology was developed that improved early prediction of compounds' clinical torsadogenic risk [13] . In 145 our study, the drug-induced arrhythmogenic risk was evaluated in diverse cell types. We found that M cells, 146 in general, are much more vulnerable to drug-induced AP prolongation and EAD generation, which suggest 147 that the intrinsic arrhythmogenicity of M cells can be much higher than that of other cell types. In addition, 148 we found that drug-induced changes in APD adaptation can be important during the evaluation of drug-149 induced cardiac toxicity. The pronounced increase in APD at slower heart rates allows for the recovery of 150 inactivated calcium or sodium channels, widening the window of EAD generation, a cellular event that can 151 induce TdP [21] [22] [23] [24] . Furthermore, we found that quinidine can generate EAD in all cell types, and the predicted 152 high TdP risk of quinidine is consistent with that in previous experimental and clinical studies. However, the 153 mechanism of drug-induced EAD generation differs across cell types; EAD generation in P cells is mostly 154 due to reactivation of INaL, while in Endo, M and Epi cells, ICaL plays the predominant role [15] . In addition, we 155 found that comparing to other cell types, P cells are generally more sensitive to drug-induced changes in AP 156 alternans at fast pacing rates, that can potentially lead to Purkinje-ventricular conduction abnormalities at 157 tissue/organ level. Interestingly, with the application of bepridil, AP alternates with beat-to-beat occurrences 158 of EAD events can be observed in M cells at slower pacing rates. These in silico findings support our 159 hypothesis that it may be insufficient to evaluate drug-induced arrhythmogenic risk in any single cell type and 160 at a given frequency. 161 We concluded that simulations of multichannel pharmacology in diverse cell types at all physiological 162 pacing rates are essential to evaluate drug-induced arrhythmogenic risks. However, the heart is a complex 163 biological system, and our study was limited at the cellular level, with no evaluation of tissue or organ level 164 complexities. For example, a recent study presented an arrhythmic hazard map for a 3D whole-ventricle model 165 8 under multiple ion channel inhibition to predict drug-induced arrhythmogenic risks. However, one advantage 166 of the series of models used in our study is its computational efficiency, which may enable large-scale in silico 167 screening for compounds of high cardiac safety, and these quantitative approaches could also offer further 168 mechanistic insights into drug-induced arrhythmogenic risk. 169 170 Methods 171 P, Endo, M, and Epi cell models were derived from the Pan-Rudy(PRd) [15] and Keith-Rudy (KRd) [16] 172 models based on experimental data on transmural heterogeneity in electrophysiology by altering GNaL, Gto1, 173 GKs and Gnaca (see Supplemental Material Table 1 for details). We simulated the application of 12 drugs [17] at 174 their EFTPCs on seven ion channels (INa, INaL, ICaL, IKr, IKs, Ito and IK1) in four cell models (see Supplemental   175 Material Table 2 for details). APD was defined as the duration from maximum dVm/dt during the AP upstroke 176 to 90% of full repolarization (APD90). All cell simulations were paced for 60 min to reach steady states. 177 To simulate a drug blocking a channel, we used the following equation to scale gx, based on the drug 178 IC50 and concentration: 
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Drug-induced changes in AP adaptations
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Drug-induced early afterdepolarization (EAD) and AP alternans
